The AML Global Portal (AGP) continues to disseminate the latest clinical updates in acute myeloid leukemia (AML), including diagnosis, prophylaxis and treatment options.
Guided by an international Steering Committee of world experts in AML, the AGP is a global online resource that provides vital information for treatment teams, including hematologists and oncologists. With an ever-expanding social media presence, the AGP engages with the global community on all major social media networks, providing a finger on the pulse of everyday, real-world clinical practice.
The AGP is designed to deliver upon an unmet need for targeted medical updates, to help treatment teams involved in AML care make informed therapeutic decisions. Last quarter, the AGP introduced new monthly educational themes. Themes so far include; treating the elderly and unfit patient, druggable mutations and MRD monitoring and clinical guidance for AML. These themes were infused with the latest clinical and translational insights gathered during the seventh annual meeting of the Society of Hematologic Oncology (SOHO) in Houston, US and the first NCRI AML academy meeting in Birmingham, UK.
The AGP is facilitated by Scientific Education Support
(SES) who love nothing more than building communities and networks to enhance the level of collective knowledge, using multichannel communications to disseminate medical advances.
The AGP would like to thank our Silver supporters AbbVie, Novartis, Daiichi–Sankyo, Roche and Genentech, Bronze supporters Celgene, Janssen
Oncology, Jazz Pharmaceuticals
and Pfizer, and contributors Agios and Helsinn, for their continued support of the initiative. This year, the AGP is proud to announce Amgen as new Silver supporter of the AGP.
For more information on the AGP, please visit: www.amlglobalportal.com. For media enquiries or to explore collaboration opportunities, please contact: email@example.com
Press release distributed by Pressat on behalf of Scientific Education Support, on Wednesday 30 October, 2019. For more information subscribe and follow https://pressat.co.uk/